摘要
被开发用于治疗中枢神经系统(CNS)疾病的药物达到临床批准的成功率是所有疾病属性中最低的。导致成功率低的很大原因是小分子透过血脑屏障(一个由毛细内皮血管紧密连接,用来排出脑内异物的屏障)的失败。血脑屏障穿透小分子的设计已然成为一个深入研究的课题,并得出了一系列用来得到血脑屏障穿透最大可能性尝试的指导。这个综述分析了筛选血脑屏障分子各种理化属性重要性排名的思考的现在情形,描述模型系统来决定血脑屏障穿透,总结数据分析方法和提供一个此领域进一步发展的前景。
关键词: 血脑屏障,药物样,中枢神经系统,神经药理学,理化性质,药物设计。
Current Medicinal Chemistry
Title:Selecting Good ‘Drug-Like’ Properties to Optimize Small Molecule Blood-Brain Barrier Penetration
Volume: 23 Issue: 14
Author(s): Paul C. Trippier
Affiliation:
关键词: 血脑屏障,药物样,中枢神经系统,神经药理学,理化性质,药物设计。
摘要: The success rate to achieve clinical approval of drugs developed to treat diseases of the central nervous system (CNS) is the lowest of all disease indications. A large contributor to this poor success rate is failure of small molecules to pass through the blood-brain barrier (BBB), a barrier composed of capillary endothelial cells connected by tight junctions that functions to extrude xenobiotics from the brain. Designing small molecules to be BBB penetrant has been the subject of intensive research and has resulted in a series of guidelines to attain the best possible chances of BBB penetration. This review will analyze the current state of thinking in ranking the importance of various physicochemical properties required to select BBB penetrant molecules, describe model systems to determine BBB penetration, summarize data analysis methods and provide an outlook on further developments in the field.
Export Options
About this article
Cite this article as:
Paul C. Trippier , Selecting Good ‘Drug-Like’ Properties to Optimize Small Molecule Blood-Brain Barrier Penetration, Current Medicinal Chemistry 2016; 23 (14) . https://dx.doi.org/10.2174/0929867323666160405112353
DOI https://dx.doi.org/10.2174/0929867323666160405112353 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cannabinoids and Neuro-Inflammation: Regulation of Brain Immune Response
Recent Patents on CNS Drug Discovery (Discontinued) Past, Present and Future of Nutrigenomics and its Influence on Drug Development
Current Drug Discovery Technologies Salen Mn Complexes are Superoxide Dismutase/Catalase Mimetics that Protect the Mitochondria
Current Inorganic Chemistry (Discontinued) Neurobiology of Depression and Novel Antidepressant Drug Targets
Current Pharmaceutical Design Transforming Growth Factor-β Signaling in Motor Neuron Diseases
Current Molecular Medicine Gene Therapy for Parkinsons and Alzheimers Diseases: from the Bench to Clinical Trials
Current Pharmaceutical Design Can Trehalose Prevent Neurodegeneration? Insights from Experimental Studies
Current Drug Targets Patent Selections
Recent Patents on Biomarkers Pharmacotherpy and Alzheimer’s Disease: The M-Drugs (Melatonin, Minocycline, Modafinil, and Memantine) Approach
Current Pharmaceutical Design Therapeutic Opportunities for Trophic Factors in Brain Inflammation
Current Pharmaceutical Analysis Minocycline and Doxycycline: More Than Antibiotics
Current Molecular Pharmacology Glutathione Peroxidase: A Potential Marker for the Most Common Diseases and Disorders
Recent Patents on Biomarkers Pharmacodynamics of Memantine: An Update
Current Neuropharmacology Application of Glutathione as Anti-Oxidative and Anti-Aging Drugs
Current Drug Metabolism Highlighting the Protective or Degenerative Role of AMPK Activators in Dementia Experimental Models
CNS & Neurological Disorders - Drug Targets Collective Roles of Molecular Chaperones in Protein Degradation Pathways Associated with Neurodegenerative Diseases
Current Pharmaceutical Biotechnology Alkaloids from Cyanobacteria with Diverse Powerful Bioactivities
Mini-Reviews in Medicinal Chemistry A New Model for Academics Based Drug Discovery
Current Alzheimer Research New Insights into Biological Markers of Frontotemporal Lobar Degeneration Spectrum
Current Medicinal Chemistry Oxidation of Potassium Channels in Neurodegenerative Diseases: A Mini- Review
CNS & Neurological Disorders - Drug Targets